Quality of life evaluated by Short Form-8 in patients with rheumatoid arthritis who were receiving infusion of infliximab

Modern Rheumatology

Volumn 19, Issue 1, 2009, Pages 27-32

  Ogawa, Hiroyasu ^a   Itokazu, Mansho ^b   Ito, Yoshiki ^a   Matsumoto, Kazu ^a   Takigami, Iori ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hirano General Hospital   (Japan)

Author keywords

Arthroplasty; Health related quality of life; Infliximab; Rheumatoid arthritis; SF 8

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG ERUPTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SHORT FORM 8;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 60149108125     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0113-5     Document Type: Article

References (19)

1. Lipsky PE, van der Heijde D, St Clair WF, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2003;343:1594-602.
2. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-63.
3. Kavanaugh A, St. Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2004;27:841-50.
4. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet. 1999;354:1932-9.
5. Felson DT, Anderson JJ, Boews M, et al. American College of Rheumatology; preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-35.
6. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts; development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
7. Fries JF, Spits P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-45.
8. Chambers LW, Macdonald LA, Tugwell P, et al. The McMaster health index questionnaire as a measure of quality of life for patients with rheumatoid disease. J Rheumatol. 1982;9:780-4.
9. Callahan LF, Pincus T. A clue from a self-report questionnaire to distinguish rheumatoid arthritis from noninflammatory diffuse musculoskeletal pain; the P-VAS: D-ADL ratio. Arthritis Rheum. 1990;33:1317-22.
10. Lorish CD, Maisiak R. The face scale; a brief, nonverbal method for assessing patient mood. Arthritis Rheum. 1986;29:906-9.
11. Ware JE, Sherbourne CD. The medical outcomes study, SF-36 item short form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83.
12. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA. 1949;140:659-62.
13. Durez P, Nzeusseu Toukap A, Lauwerys BR, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis. 2004;63:1069-74.
14. Maini RN, Breedveld FC, Kalden JR, et al. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051-65.
15. Russell AS, Conner-Spady B, Mintz A, et al. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol. 2003;30:941-7.
16. Birrell FN, Hassell AB, Jones PW, et al. How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study. Clin Rheumatol. 2000;19:195-9.
17. Jette AM. Functional status index; reliability of a chronic disease evaluation instrument. Arch Phys Med Rehabil. 1980;61:395-401.
18. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis; the arthritis impact measurement scales. Arthritis Rheum. 1980;23:146-52.
19. Turner-Browker DM, Bayliss MS, Ware JE Jr, et al. Usefulness of the SF-8 health survey for comparing the impact of migraine and other conditions. Qual Life Res. 2003;12:1003-12.